



**Figure 1.** Ultrasound demonstrated a well-circumscribed mass at the upper mediastinum of the right testis with a hyperechoic periphery and hypoechoic center (arrows). Doppler showed more vascularization at the periphery and less vascularization at the center of the mass.




**Figure 2.** Macroscopic view of the tumor.



**Figure 3.** Hyalinized (x), solid (\*), and tubular areas (arrow-head) (HEX50).



**Figure 4.** Rete testis invasion by the tumor cells (HEX50).



**Figure 5.** Inhibin (a), calretinin (b), and Melan A (c) positivity of the tumor cells (x50).

membrane antigen (EMA), Common Acute Lymphoblastic Leukemia Antigen (CD10), Placental alkaline phosphatase (PLAP), OCT3/4 (Octamer-binding transcription factor), and  $\alpha$ -fetoprotein (AFP). The area with diffusely arranged tumor cells was 10% positive for p53.

In this case, tumor cells do not exhibit specific histological and immunohistochemical properties congruent with sex cord-stromal cell tumors such as Leydig cell tumors, Sertoli cell tumors, or granulosa cell tumors. With positive immunostaining for sex cord-stromal tumors and evaluation of the morphologic properties, we diagnosed this case as an undifferentiated sex cord-stromal testis tumor.

### Discussion

Sex cord-stromal tumors of the testis are rare. They are more commonly seen in the pediatric age group than adults and represent the second largest group of primary

testicular tumors after germ cell tumors [2,4–6]. This group consists of (a) pure tumors consisting of Leydig cell tumors, Sertoli cell tumor, granulosa cell tumors, tumors in the fibroma thecoma group, and (b) mixed and unclassified type sex cord-stromal tumors [2,3].

Sex cord-stromal tumors may cause gynecomastia, Cushing’s syndrome, or isosexual pseudoprecocity puberty, or present as a component of Peutz Jegher or Carney syndromes [2,5,6]. In our case, we found no additional clinical findings other than testicular mass which was diagnosed in ultrasonography. Both Leydig cell tumors and Sertoli cell tumors may have intracytoplasmic vacuoles due to the lipid content of the cytoplasm [2,5,6]. 30–35% of cases with Leydig cell tumors may present with Reinke crystals in the eosinophilic cytoplasm [6,7]. Immunohistochemistry may help if the morphology is not characteristic or diffuse spindle or clear cell formations are



present. In sclerosing Sertoli cell tumors, more than 50% of the tumor volume has hypocellular collagenous stroma [2,6]. Intratubular large cell hyalinizing Sertoli cell neoplasia is the intratubular neoplastic proliferation of large Sertoli cells with eosinophilic cytoplasm with prominent deposits of the extracellular basement membrane [2,6].

Tumors having two or more distinct forms of sex cord-stromal elements and tumors showing indeterminate differentiation of the tumor cells are classified as mixed and unclassified sex cord-stromal tumors, respectively, by the WHO-2016 classification system [2]. The undifferentiated sex cord-stromal tumors reported in the literature histologically have predominant spindle cells [4,8–10]. In our case that has solid, nodular, and tubular areas, we did not identify any spindle cell areas.

Sex cord-stromal tumors are rare, and they usually have a good prognosis. However, in 10% of the cases, metastases can be seen [3,11,12]. Pathological risk factors have been defined to determine the malignancy potential. These criteria are defined based on the evaluation of orchiectomy specimens: (a) tumor size (tumors larger than 5 cm diameter), (b) infiltrating margins, (c) cytologic atypia, (d) greater than 5 mitotic features per 10 high-power fields, (e) lymphovascular invasion, and (f) necrosis [7]. Patients with two or more of these criteria may require close clinical follow-up, as the potential for malignancy may be high.

Thoracoabdominal computed tomography scans were done for tumor staging which showed no distant metastasis or pathologic lymph nodes. After radical inguinal orchiectomy, the patient was interpreted as “limited to the testis (pT1)” according to the cancer classification of TNM (TNM classification system. T: extent of the primary tumour, N: the absence or presence and extent of regional lymph node metastasis, M: the absence or presence of distant metastasis) [13]. After pathologic diagnosis and tumor staging, the patient was informed about the rarity of his disease and suggested treatment strategies with their complications. Lymph node sampling was suggested; however, the patient refused the surgery due to its complications (possibility of retrograde ejaculation). Therefore, the patient was taken into close follow-up. The patient was not a high-risk patient for detecting contralateral carcinoma in situ (CIS), i.e., with a testicular volume of less than 12 ml, no history of cryptorchidism, and any ultrasonographic abnormalities. No biopsy or fixation was done to the other normal testis. The patient is disease-free in the post-operative 7th month of the surgery.

## Conclusion

Although sex cord-stromal tumors of the testis are rare, there are no standardized treatments and follow-up models for undifferentiated types in the literature because these studies are usually short-term clinical follow-ups and case

reports. In our opinion, advances in molecular genetics, immunohistochemistry in combination with larger clinical series, will help the diagnosis and treatment of these cases in the future.

## Acknowledgement

None.

## List of abbreviations

AFP	Alpha-fetoprotein
hCG	β-human chorionic gonadotropin
LDH	Lactate dehydrogenase

## Consent for publication

Informed consent was obtained from the patient.

## Ethical approval

Ethical approval is not required at our institute to publish an anonymous case report.

## Author details

Asli Muratli<sup>1</sup>, Askin Eroglu<sup>2</sup>, Aysen Terzi<sup>3</sup>, Ugur Mungan<sup>4</sup>, Mustafa Secil<sup>4</sup>

1. Baskent University, Department of Pathology and Laboratory Medicine, Izmir, Turkey
2. Baskent University, Department of Urology, Izmir, Turkey
3. Baskent University, Department of Pathology and Laboratory Medicine, Ankara, Turkey
4. Dokuz Eylül University Faculty of Medicine, Department of Radiology, Izmir, Turkey

## References

1. Smith ZL, Werntz RP, Eggen SE. Testicular cancer epidemiology, diagnosis, and management. *Med Clin North Am* 2018; 102(2):251–64. <https://doi.org/10.1016/j.mcna.2017.10.003>
2. Idrees MT, Ulbright TM, Oliva E, Young RH, Montironi R, Egevad L, et al. The World Health Organization 2016 classification of testicular non-germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. *Histopathology* 2017; 70(4):513–21. <https://doi.org/10.1111/his.13115>
3. Silberstein JL, Bazzi WM, Vertosick E, Carver BS, Bosl GJ, Feldman DR, et al. Clinical outcomes of local and metastatic testicular sex cord-stromal tumors. *J Urol* 2014; 192(2):415–9. <https://doi.org/10.1016/j.juro.2014.01.104>
4. Sewell J, Osborne JR, Basto M, Sapre N, Kostos P, Raj M. Unclassified sex cord-stromal tumour of the testis—how to diagnose the unclassified. *J Clin Urol* 2017; 11:372–5. <https://doi.org/10.1177/2051415817739715>
5. Bremner F, Behnes CL, Radzun HJ, Bettstetter M, Schweyer S. Tumoren des Gonadenstromas. *Pathologie* 2014; 35(3):245–51. <https://doi.org/10.1007/s00292-014-1901-7>
6. Roth LM, Lyu B, Cheng L. Perspectives on testicular sex cord-stromal tumors and those composed of both germ cells and sex cord-stromal derivatives with a comparison to corresponding ovarian neoplasms. *Human Pathol* 2017; 65:1–14. <https://doi.org/10.1016/j.humpath.2017.04.009>
7. Kim I, Young RH, Scully RE. Leydig cell tumors of the testis. A clinicopathological analysis of 40 cases and review of the literature. *Am J Surg Pathol* 1985; 9:177–92.

8. Brekelbaum CE, Abreo F, Fowler M, Kubricht WS, Eastham JA. Undifferentiated sex cord/stromal testis tumor. *Urology* 2000; 55(3):436. [https://doi.org/10.1016/S0090-4295\(99\)00482-3](https://doi.org/10.1016/S0090-4295(99)00482-3)
9. Tarjan M, Sarkisov G, Tot T. Unclassified sex cord/gonadal stromal testis tumor with predominance of spindle cells. *Acta pathologica, microbiologica, et immunologica Scandinavica* 2006; 114(6):465–9. [https://doi.org/10.1111/j.1600-0463.2006.apm\\_400.x](https://doi.org/10.1111/j.1600-0463.2006.apm_400.x)
10. Magro G, Gurrera A, Gangemi P, Saita A, Greco P. Incompletely differentiated (unclassified) sex cord/gonadal stromal tumor of the testis with a ‘pure’ spindle cell component: report of a case with diagnostic and histogenetic considerations. *Pathol Res Pract* 2007; 203:759–62. <https://doi.org/10.1016/j.prp.2007.05.011>
11. Sesterhenn IA, Cheville J, Woodward PJ, Damjanov I, et al. Sex cord/gonadal stromal tumours. In pathology and genetics of tumours of the urinary system and male genital organs. In: Eble JN, Sauter G, Epstein JI, et al., editors. *World Health Organization classification of tumours*. Lyon: IARC Press; 2004, p 251.
12. Rove KO, Maroni PD, Cost CR, Fairclough DL, Giannarini G, Harris AK, et al. Pathologic risk factors for metastatic disease in postpubertal patients with clinical stage I testicular stromal tumors. *Urology* 2016; 97:138–44. <https://doi.org/10.1016/j.urology.2016.06.066>
13. Brierly JD, Gospodarowicz MK, Wittekind C, eds. *TNM classification of malignant tumours*. 8th ed. Oxford: Wiley; 2017 (e-book).

**Summary of the case**

<b>Patient (gender, age)</b>	1	19 years-old, male
<b>Final Diagnosis</b>	2	Undifferentiated sex-cord stromal tumor of the testis
<b>Symptoms</b>	3	Painful enlargement of the testis
<b>Medications</b>	4	Radical orchiectomy
<b>Clinical Procedure</b>	5	Close clinical follow-up
<b>Specialty</b>	6	Urologic oncology